Morgan Stanley analyst Michael Ulz has maintained their bullish stance on MIRM stock, giving a Buy rating on April 25.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Michael Ulz has given his Buy rating due to a combination of factors, including Mirum Pharmaceuticals’ strong financial performance and promising future prospects. The company’s first-quarter 2025 sales of Livmarli surpassed expectations, reaching $73.2 million compared to the anticipated $64.7 million. This performance indicates a steady demand for Livmarli in treating Alagille syndrome and progressive familial intrahepatic cholestasis (PFIC), with additional growth expected from new market approvals, such as in Japan.
Furthermore, Mirum’s management has raised their 2025 net sales guidance to a range of $435-$450 million, up from the previous $420-$435 million. The company’s pipeline remains robust, with significant progress in their volixibat program, including upcoming data releases for its use in primary biliary cholangitis and primary sclerosing cholangitis. These developments, coupled with the recent approval of Livmarli’s tablet formulation, are likely to drive further growth and flexibility, supporting the Buy rating.
In another report released on April 25, Evercore ISI also maintained a Buy rating on the stock with a $68.00 price target.
Based on the recent corporate insider activity of 39 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of MIRM in relation to earlier this year.